Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
SAN Stock Chart & Stats
€86.33
€0.05(0.05%)
At close: 4:00 PM EST
€86.33
€0.05(0.05%)
Day’s Range― - ―
52-Week Range€76.15 - €110.88
Previous CloseN/A
Volume78.83K
Average Volume (3M)2.23M
Market Cap
$105.26B
Enterprise Value€108.37B
Total Cash (Recent Filing)$15.36B
Total Debt (Recent Filing)$22.29B
Price to Earnings (P/E)11.7
Beta0.80
Next Earnings
Oct 24, 2025EPS Estimate
2.7Last Dividend Ex-Date
May 12, 2025Dividend Yield4.54%
Share Statistics
EPS (TTM)1.59
Shares Outstanding1,227,469,000
10 Day Avg. Volume1,728,848
30 Day Avg. Volume2,227,921
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit3.51
Enterprise Value/Ebitda11.45
Forecast
1Y Price Target
$105.31Price Target Upside21.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Earnings GrowthSanofi's focus on FY26 margin improvements suggests potential for an EPS upgrade cycle, which is key for the company's financial performance.
Market OpportunitiesThe potential launch of Sanofi's tolebrutinib for non-relapsing secondary progressive multiple sclerosis is anticipated to capture a significant market opportunity, with peak sales modeled at Eur2bn.
R&D And Product DevelopmentSanofi's R&D spending is considered appropriate and supports the thesis of margin expansion.
Bears Say
Pipeline DisappointmentsSanofi experienced disappointments in key pipeline projects, such as the failure of itepekimab for COPD and weaker than expected results for amlitelimab in atopic dermatitis.
Product Efficacy ConcernsThe results represent a material step down in efficacy from the Ph2b trial and fall short of Dupixent’s Week 16 performance.
Product Launch ChallengesThere is a debate about whether tolebrutinib's label will require weekly liver monitoring, which could impact its launch trajectory.
Sanofi News
SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €76.15 and its highest was €110.88 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $105.26B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 24, 2025 which is in 6 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 31, 2025. The company reported €1.59 earnings per share for the quarter, missing the consensus estimate of €1.638 by -€0.048.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €3.92 which represents an annual dividend yield of 4.54%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 2.7.
How many shares outstanding does Sanofi have?
Sanofi has 1,227,469,000 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €1.59 in its last earnings report, missing expectations of €1.638. Following the earnings report the stock price went down -7.811%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in FR:SAN
Company Description
Sanofi
Sanofi is a global healthcare company headquartered in Paris, France, specializing in pharmaceuticals and vaccines. The company operates in several key sectors, including prescription pharmaceuticals, vaccines, consumer healthcare products, and rare diseases. Sanofi's core products include a wide range of medications for diabetes, cardiovascular diseases, immunology, and oncology, as well as vaccines under its Sanofi Pasteur division.
SAN Company Deck
SAN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Sanofi reported strong growth and successful new product launches, with significant gains in Dupixent and vaccines. Strategic acquisitions and sustainability leadership were also positive. However, challenges in the flu market and mixed results for itepekimab in COPD, along with potential future tariff impacts, present areas of concern.View all FR:SAN earnings summariesSAN Stock 12 Month Forecast
Average Price Target
€105.31
▲(21.99% Upside)
Technical Analysis
Options Prices
Currently, No data available
---